Electrochemotherapy is the combined use of a chemotherapeutic agent and pulsed electric fields. Electrical treatment causes an increase in cell membrane permeability which allows the chemotherapeutic agent to more freely enter the tumor cells. Electrochemotherapy has been under development in clinical trials. This study focused on determining the applicability of electrochemotherapy for treating soft tissue sarcoma using an animal model bearing human sarcomas. The antitumor effects of several concentrations of cisplatin, bleomycin, doxorubicin, and netropsin as single agents delivered with electric pulses were investigated based on post-treatment tumor volumes and histology. Electrochemotherapy treatment resulted in 5% to 88.9% durable complete responses; ECT that employed bleomycin resulted in the highest antitumor effects. This indicates the feasibility of electrochemotherapy as a modality for limb preserving treatments for sarcoma of the extremities.
Introduction
Soft tissue sarcoma most frequently affects young productive individuals, and approximately 60 percent of soft tissue sarcomas occur in the extremities (1, 2). Treatment for this disease is challenging. Historically, the primary treatment for these tumors has been amputation and compartmental resection (3, 4) . Over the past 20 years, however, the treatment for soft tissue sarcoma of the extremities has gradually changed from radical surgery to limb-sparing approaches. These newer approaches combine wide local excision with adjuvant treatment consisting primarily of radiation (4) (5) (6) (7) . The 5-year local recurrence rate of for this multimodality approach is approximately 15 percent (5-7). Interestingly, there is no measurable increase in overall survival when compared to amputation (5, 6) .
These current limb sparing procedures are not amenable to all adult soft tissue sarcomas of the extremity. Amputation is still used as a treatment in a fraction of tumors that occur close to joints, bone, or neurovascular bundles. Therefore, innovative limb sparing procedures that can achieve local control with minimal morbidity and disability are important for furthering treatment of soft tissue sarcoma of the extremities.
A novel drug delivery method known as electrochemotherapy (ECT) has recently emerged as a treatment with a wide range of potential applications for cancer. The treatment consists of administering an antineoplastic agent followed by the localized delivery of pulsed electric fields to the tumor. Electric pulses increase cell membrane permeability which allows exogenous molecules to enter the cells (8, 9) . This process of permeabilization is called electroporation. The combined use of electroporation and chemotherapy is known as electrochemotherapy.
Electrochemotherapy has been shown to be an effective anticancer treatment in a variety of animal models for different types of cancers (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Typically, complete response rates vary from 60 to 100 percent. The efficacy of electrochemotherapy has also been demonstrated in several recent clinical trials for melanoma, basal cell carcinoma, and head and neck squamous cell carcinoma (22) (23) (24) (25) (26) (27) (28) (29) . Complete response rates vary from 33 percent to 96 percent in these human trials. ECT could potentially be a novel limb-sparing procedure for the effective local control of soft tissue sarcomas of the extremities. Therefore, this study was conducted to investigate the efficacy of electrochemotherapy for treating human sarcomas established in the rear limbs of athymic rats. The antitumor effects of single and multiple ECT treatments were determined along with the histologic events that result from treatment.
Materials and Methods

Sarcoma Cell Line and Culture
Human A204 rhabdomyosarcoma cells (HTB 82; American Type Culture Collection, Rockville, MD, USA) were utilized for this study. A204 cells were grown in McCoy's 5A medium (Mediatech, Washington, DC, USA) supplemented with 10 percent (v/v) fetal bovine serum (PAA Laboratories, Newport Beach, CA, USA) and 90 µg/ml gentamicin sulphate (Gibco, Grand Island, NY, USA). Cells were grown at a temperature of 37º C in a humidified atmosphere that contained 5 percent CO 2 . Confluent cultures were prepared for use by trypsinization followed by 3 washes in phosphate buffered saline. Trypan blue dye exclusion was used to determine the viability of all harvested cell batches. Viability was greater than 90 percent for all A204 batches used in this study.
Anesthesia
Animals were first placed in an induction chamber that was charged with 5 percent isoflurane (IsfoFlo, Abbott Laboratories, North Chicago, Il, USA) in oxygen for several minutes. Rats were then fitted with a standard rodent mask supplied with 3 percent isoflurane to maintain anesthesia during procedures.
Tumor Induction
Athymic rats (Harlan Sprague Dawley, Inc., Indianapolis, IN, USA) that were 3-4 weeks old at the time of tumor induction were used for this study. Tumors were induced by injecting 7x10 6 cells, contained in 70 µl of saline, into the biceps femoris muscle of both rear limbs of the athymic rats. Tumor cells were injected just beneath the superficial fascia covering the muscle using a 5/8 inch 25 gauge needle. Athymic animals were selected for this investigation because the human sarcoma cell line could be grown in them due to their lack of an immune system. Tumors were allowed to grow to volumes that were approximately 200 mm 3 prior to initiating any treatment. This required approximately 7-10 days.
Tumor Treatment
Animals bearing sarcomas in both hind limbs were randomly divided into appropriate treatment groups. These groups were designated as follows: D-E-, no treatment; D+E-, drug only; D-E+, electrical treatment only; and D+E+ drug followed by pulses. All D+ groups also carried designations to indicate the drug and dose that was administered.
The chemotherapeutic agents used for this study were bleomycin (Blenoxane, Bristol-Meyers Squibb, Princeton, NJ, USA), Cisplatin, (cis-Platinum(II)-Diammine Dichloride, Sigma, St. Louis, M.O., USA), Doxorubicin (adriamycin, Sigma, St. Louis, MO, USA), and Netropsin (Crescent Chemical Company, Inc, Hauppauge, NY, USA). Doxorubicin was chosen for investigation as it has been used alone and in combination for treating sarcoma (30,31). Bleomycin and cisplatin were selected for use because their antitumor effects have been shown to be augmented when electric pulses were used to facilitate cellular uptake in other studies (10-28). Netropsin has shown similar increases in cytotoxicity when delivered to cells in vitro using pulsed electric fields (9).
Electrochemotherapy consisted of an intratumor injection of one of these drugs. A volume equivalent to 50 percent of the measured tumor volume was administered by a single point injection to the center of the tumor. All injections were carried out using a 1/2 inch 30 gauge needle. Animals that did not receive drug injections were given an intratumor injection of saline that was equal to 50 percent of the tumor volume. Injection volumes equal to 50 percent of the tumor volume were a maximum amount of fluid that could be administered. This volume was selected to maximize tumor perfusion.
Electrical treatment was administered 10 minutes after each tumor was injected to complete the ECT treatment. An electrode comprised of six 25 gauge needles equispaced around a 1 cm diameter circle (19) was inserted so that the tips of the needles were slightly beyond the depth of the tumor. The electrode was inserted so that the needles were in the perimeter of the tumors. Six rectangular pulses that were 100 µs in duration were then administered to the tumors using a MedPulser ® generator (Genetronics, San Diego, CA) The ratio of the applied voltage for each pulse to the electrode spacing (nominal electric field strength) was 1300 V/cm. For the case of tumors that were not scheduled to receive electric pulses, the needle array was inserted but no pulses were administered in order to provide an appropriate sham electrical treatment.
Part of the experimental work in this study was designed to examine the effects of multiple ECT treatments administered to the same tumor. After administering a first ECT treatment, tumors that recurred were given a maximum of two more ECT treatments. These treatments were administered when a palpable tumor within the original treatment site was first detected during routine follow up.
Tumor Measurement
Tumor dimensions were measured immediately prior to electrochemotherapy treatment and at 7 day intervals after treatment. Three mutually orthogonal measurements were taken (a, b, c) using a digital Vernier caliper. Tumor volumes were then computed using the formula V = abcΒ/6.
Post-treatment Monitoring
The tumor volumes of anesthetized animals were determined after treatment as described above. Tumor volumes from each rat were compared to their respective volumes on the day of first treatment. Responses to both single and multiple ECT were scored 28 days after the first treatment as follows: progressive disease (PD), increased tumor volume; stable disease (SD), less than 50 percent decrease in tumor volume; partial response (PR), greater than 50 percent decrease in tumor volume; and complete response (CR), no detectable disease. Animals that responded completely and maintained that state until day 100 were considered cures.
Histology
Histologic specimens were excised at scheduled times after treatment in order to elucidate details of tumor regression resulting from ECT. For these samples, the entire tumor/treatment site was harvested for analysis. All samples were submitted entirely for histologic examination. After fixation in 10 percent neutral buffered formalin for 12 hours, the specimens were processed using routine paraffin embedding methods to obtain tissue sections representative of the entire tumor/treatment site. These sections were then stained with hematoxylin and eosin (H&E, Richard-Allan Scientific, Kalamazoo, MI) using standard histologic techniques. Sections were graded for the fractions of the total area that were viable, necrotic, and apoptotic.
Results
Single ECT Treatment using Different Chemotherapeutic Agents and Doses
Rats bearing bilateral sarcomas in the rear limbs were randomized into one D-E-, one D-E+, four D+E-, and fourteen D+E+treatment groups containing approximately 6 tumors per group. Either cisplatin, bleomycin, doxorubicin, or netropsin was then delivered using pulsed electric fields to each tumor in the D+E+ groups. Different concentrations of each agent were used for animals that received a complete treatment (D+E+). Animals that received drug alone (D+E-) were given the highest dose of each agent. This experimental design was executed a total of 3 times which resulted in about 18 tumors per treatment condition. Mean tumor volumes and response data are shown in Table I .
The results shown in Table I indicate that tumors in the D-Eand D-E+ groups were considerably larger on day 28 than on day 0 (day of treatment); these tumors continued to grow throughout the experiment. No partial responses, complete responses, or cures were observed in these groups. Similarly, the D+E-groups that received either 1.6 mg/ml cisplatin, 8 U/ml bleomycin, 10 mg/ml doxorubicin, or 4 mg/ml netropsin by direct intratumor injection did not respond. No partial responses, complete responses, or cures resulted from these highest doses of the four agents. However, responses were obtained when administration of the drugs was combined with electrical treatment. Table I indicates that the combination of cisplatin and electrical treatment resulted in 22.2-33.3 percent complete responses and 16.7 -33.3 percent cures over four different concentrations (0.2, 0.4, 0.8, and 1.6 mg/ml) tested. Four different concentrations of bleomycin (1, 2, 4, and 8 U/ml) were also tested as the drug component of ECT. The number of complete responses on day 28 post treatment ranged from 38.9 -61.1 percent and was dose dependent. The cure rate ranged from 30.7 to 72.2 percent. Bleomycin concentrations of 4 U/ml and 8 U/ml both resulted in the same cure rate. Cure rates for 5 mg/ml and 10 mg/ml doxorubicin were 5.6 and 33.3 percent, respectively. Four different concentrations of netropsin were used. The two highest, 2 mg/ml and 4 mg/ml resulted in cure rates of 5 and 22.2 percent respectively. The two lower doses (0.5 and 1 mg/ml) produced low complete response rates and no cures. From these data, it is clear that by day 28 partial responses were rare, and animals were either complete responders or had disease that progressed. In addition, bleomycin produced the highest number of complete responders and highest cure rate; the 4 U/ml bleomycin concentration was identified as optimal as it represented the lowest concentration to achieve the maximum cure rate in the data set.
Multiple ECT Treatment using Optimized Dose and Chemotherapeutic Agent
The use of 4 U/ml bleomycin was further investigated in a multiple ECT protocol. Treatment included administering ECT up to two additional times to animals that failed to maintain complete response status; partial ECT treatment in the form of pulses alone and drug alone was also performed mul-tiple times. Rats were randomized into D-E-, D-E+, D+E-, and D+E+ treatment groups containing 6 tumors per group; each animal had bilateral tumors that were approximately 200 mm 3 . This experiment was executed a total of three times to yield, upon pooling data, 18 tumors per treatment group. Table II shows the results of applying ECT multiple times for sarcomas. A 94.4 percent complete response rate was achieved which compares favorably to the 44.4 percent com-plete response rate achieved using a single ECT treatment that utilized the same 4 U/ml bleomycin dose. The 88.9 percent cure rate for multiple treatment also compared favorably to the 72.2 percent cure rate for a single treatment.
Histologic Events That Occur After Treatment
A histologic study was initiated in order to elucidate details of tumor regression resulting from ECT with 4 U/ml A. PD -progressive disease, tumor volume increased as evaluated on day 28 following post treatment B. SD -stable disease, < 50% decrease in tumor volume as evaluated on day 28 following post treatment C. PR -partial response, > 50% decrease in tumor volume as evaluated on day 28 following post treatment D. CR -complete response, no palpable tumor present as evaluated on day 28 following post treatment. E. Cure -no evidence of tumor at 100 days after treatment F. One PD animal died before day 28, included as PD in day 28 data G. Two PD animals died before day 28, included as PD in day 28 data A. PD -progressive disease, tumor volume increased as evaluated on day 28 following post treatment B. SD -stable disease, < 50% decrease in tumor volume as evaluated on day 28 following post treatment C. PR -partial response, > 50% decrease in tumor volume as evaluated on day 28 following post treatment D. CR -complete response, no palpable tumor present as evaluated on day 28 following post treatment. E. Cure -no evidence of tumor for 100 days after treatment bleomycin. Four basic treatment groups, D-E-, D+E-, D-E+, and D+E+, were treated. Each of these groups contained 20 tumors. On days 3, 7, 10, 14, and 21 after treatment, four tumors from each group were harvested for histological analysis after humane euthanasia. Representative paraffin embedded sections were examined to determine the fraction of the tumor sections that were necrotic, apoptotic, and viable. Mean data was computed for each tumor; these data were combined into mean values for each group. Figure 1 shows the mean percentage of necrosis and apoptosis for each treatment group at the four time points. The D-E-, D+E-, and D-E+ animals had considerably lower levels of necrosis than tumors from the D+E+ group. In contrast, at least 75 percent of the tissue in the D+E+ groups was necrotic over the course of the study. This indicates that a rapid necrosis in the dominant means of tumor cells death. Necrosis increased to 97.9 percent on day 21. Apoptosis appeared to be more pronounced days 3 and 7 in the D+E+ group.
The size of the tumors in animals that were in the D-E-, D+E-, and D-E-groups increased in size over the 21 day histologic study. The percentages of necrosis and apoptosis in tumors from these treatment groups did not show a clear trend. In contrast, animals that received both bleomycin and electrical treatment decreased in size during the course of the experiment starting on day 3. Figure 2 shows examples of the necrosis and apoptosis in these tumors and provides details about the criteria used to evaluate these effects.
Discussion
This study examined the effects of bleomycin, cisplatin, netropsin, and doxorubicin used as single agents delivered by pulsed electric fields to sarcomas in an animal model. Bleomycin produced the highest percentages of animals with complete responses. The durable complete response rate for a single ECT treatment was 72.2 percent for two concentrations of the drug, 4 and 8 U/ml, indicating no increased effect from the higher dose. Other studies have shown bleomycin to be effective (10-,11, 13-20) . These other studies include a preliminary investigation in the same model (32) nearly identical except that the preliminary study used a bleomycin injection volume equal to 25 percent of the tumor volume. In contrast, the current study utilized a volume equal to 50 percent of the tumor volume which probably contributed to the increased cure rate by providing more complete perfusion of the cells within the tumor.
The other single agents used for this study did result in complete responses and cures indicating that pulsed electric fields augmented their effectiveness. However, these rates were considerably lower than those obtained with bleomycin. ECT using cisplatin resulted in long term complete response rates that were up to 33.3 percent; this was roughly half of the rate obtained using 4 U/ml bleomycin. Cisplatin has resulted in responses in several other ECT studies in animal models (12, 33) and the clinic (34). Doxorubicin also resulted cures in 33.3 percent of the animals using the highest concentration tested, this is an interesting result as the drug resulted in no cytotoxicity increases when electroporation was used to deliver it in in vitro (35, 36) . Netropsin resulted in the lowest cure rate of the 4 agents; 22.2 percent resulted using a 4 mg/ml concentration.
The multiple treatment protocol used for this study allowed for up to two additional ECT treatments. These were administered to tumors that recurred at a time when the recurrence was first detected. This tactic, which used 4 U/ml bleomycin, augmented the cure rate to 88.7 percent which was an increase over the 72.2 percent cure rate for a single ECT treatment. Multiple ECT treatments also showed a similar increase in the day 28 complete response rate. These data indicate that ECT can be applied multiple times for an improved response. The fact that the animals lacked a sufficient immune system may have played a role in achieving and maintaining complete responses as the actions of the immune system have been shown to effect responses to ECT (37-39).
Single and multiple ECT was tolerated well by the animals. The hind limbs had no functional impairment during the follow up period. It was clear from the histologic specimens that the primary effect of ECT on the tumors was necrosis when bleomycin was used as the drug. This effect was quite rapid as greater than 70 percent of each tumor was necrotic 3 days after treatment. This strong antitumor effect coupled with the mantenence of function is definitely desirable for treating soft tissue sarcoma. To further support the continued translation of ECT for sarcoma, a recent study examined the effects of ECT with bleomycin on normal skin, muscle, nerve, and blood vessel in a rat model (40). Modest adverse effects were detected in these normal tissues when bleomycin doses and electric pulse application were identical to those used to treat sarcomas in this study. Significant adverse effects only resulted from high drug concentrations and multiple electrical treatments performed on the same site during the same ECT session. These effects were shown to subside over time regardless of their severity.
Doxorubicin is currently a commonly used agent used against in sarcoma. When it is used singly or in combination 15 to 25 percent objective tumor responses are obtained in adult soft tissue sarcoma (41). In contrast, It has been shown that bleomycin has little activity against soft tissue sarcoma (42) when given in conventional intravenous doses of 20 U/m 2 /week (total dose of 240 U/m 2 ). However, this study resulted in an 88.9 durable complete response rate when bleomycin was combined with electroporation. The dose required to achieve this rate was much smaller than would be used for systemic bleomycin treatment. From the standpoint of minimizing side effects due to chemotherapy, ECT by its nature would minimize these effects as it employs very low bleomycin dose.
Therapy of adult soft tissue sarcoma consists primarily of surgery combined with radiation. This multimodal approach has greatly decreased the amputation rate but has not changed survival. It is envisioned that the maximum benefit of electrochemotherapy can be realized when used as part of a multimodality approach to sarcoma limb sparing procedures. ECT can be an integral part of limb sparing procedures for extremity soft tissue sarcoma by producing rapid chemotherapeutic cytoreduction as well as high durable complete response rates. This may permit surgical procedures that are less radical than those that are normally required. In addition, ECT can be used in areas where surgery could lead to great disability such as near vital structures. ECT can also be used for the treatment of multiple recurrences when wide local excision is not possible due to a lack of normal surrounding tissue and amputation is the only option.
